ARWR Milestones

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Published August 13, 2025 at 08:10 PM

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to Arrowhead. This agreement pertains only to the $100 million milestone, which was announced on July 28, 2025, and earned after Arrowhead reached the first of two prespecified enrollment tar

Related Questions

How will the $100 million milestone payment from Sarepta affect Arrowhead’s cash balance and liquidity in the short term? What is the expected impact of the $50 million cash and $50 million stock redemption on Arrowhead’s share count and earnings per share (EPS)? Will the issuance of $50 million of Arrowhead common stock dilute existing shareholders, and how is the dilution being priced? What are the tax implications of receiving $50 million in cash versus $50 million in stock for Arrowhead and its shareholders? Is the cash component being held in a low‑interest account or earmarked for specific R&D or pipeline milestones? How might the market price Arrowhead’s stock in response to the redemption—will we see a short‑term price dip or a longer‑term upside from the partnership validation? What is the timeline for the second enrollment milestone and what additional cash or stock payments could be required? How will this milestone affect the valuation of Arrowhead’s pipeline assets, particularly the programs co‑developed with Sarepta? Will the cash and stock receipt have any impact on Arrowhead’s upcoming conference calls, guidance revisions, or analyst coverage? How does this milestone payment compare to similar partnership milestones in the RNA‑targeting space and to Arrowhead’s historical cash‑flow profile? Does the receipt of this milestone trigger any covenants or changes in Arrowhead’s credit facilities or debt ratios?